Publications

1. Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J. 2024 Nov 6; 14 (1):193 Epub 2024 Nov 06
   View PubMed
2. Glimelius I, Kleinstern G, Robinson DP, Mansouri L, Rostgaard K, Hjalgrim H, Niemann CU, Mattsson M, Rabe KG, Hampel PJ, Parikh SA, Rosenquist R, Cerhan JR, Slager SL, Smedby KE. Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia. EJHaem. 2024 Oct; 5 (5):998-1004 Epub 2024 Aug 27
   View PubMed
3. Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2024 Sep 27 Epub 2024 Sept 27
   View PubMed
4. Truong HL, Barreto JN, Mara KC, Hampel PJ, Micallef IN, Nowakowski GS, Thanarajasingam G, Thompson CA, Wang Y, Witzig TE, Herrmann SM, Leung N. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncol Pract. 2024 Jun; 20 (6):797-807 Epub 2024 Feb 26
   View PubMed
5. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8 (10):2342-2350
   View PubMed
6. Abdelbaky SB, Giacopelli B, Rabe KG, Yamaguchi K, Wu YZ, Yan H, Shanafelt TD, Parikh SA, Ding W, Hampel PJ, Brown S, Cerhan JR, Vachon CM, Kay NE, Hanson CA, Parker AS, Braggio E, Slager SL, Oakes CC. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature. Blood. 2024 Apr 25; 143 (17):1752-1757
   View PubMed
7. Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncol. 2024 Apr; 6 (2):251-263 Epub 2024 Apr 16
   View PubMed
8. Kosydar SR, Parikh SA, Lester SC, Rabe KG, Ding W, Burlile JF, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Schwager SM, Slager SL, Kay NE, Call TG, Breen WG, Hampel PJ. Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment. Am J Hematol 2023 Nov; 98 (11):E318-E321 Epub 2023 Aug 24
   View PubMed
9. Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 Sep; 34 (9):796-805 Epub 2023 July 04
   View PubMed
10. Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O'Brien DR, Boddicker NJ, Kleinstern G, Rabe KG, Bruins L, Brown S, Bonolo de Campos C, Ding W, Leis JF, Hampel PJ, Call TG, Van Dyke DL, Kay NE, Cerhan JR, Yan H, Slager SL, Braggio E. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 2023 Jul 11; 7 (13):3169-3179
    View PubMed
11. Hampel PJ, Parikh SA. Correction: Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022 Dec 22; 12 (12):172
    View PubMed
12. Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022 Nov 29; 12 (11):161
    View PubMed
13. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
14. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
15. Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: A continuing evolution in care. Blood Rev. 2022 Jul; 54:100930 Epub 2022 Jan 26
    View PubMed
16. Salama Y, Zhao F, Oliveira JL, Yuan J, Jevremovic D, Go RS, Ding W, Parikh SA, Shah MV, Hampel PJ, Al-Kali A, Morice WG, Shi M. Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer J. 2022 Feb 22; 12 (2):30
    View PubMed
17. Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 Jan 1; 97 (1):90-98 Epub 2021 Nov 05
    View PubMed
18. Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, Nowakowski GS, Thompson CA, Maurer MJ, Wenzl K, Novak AJ, Wu X, Habermann TM, Witzig TE. The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica. 2021 Aug 1; 106 (8):2261-2264 Epub 2021 Aug 01
    View PubMed
19. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
20. Hampel PJ, Parikh SA, Call TG. Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. Leuk Lymphoma. 2021 Jun; 62 (6):1289-1301 Epub 2021 Jan 07
    View PubMed
21. Tian S, Zhang H, Zhang P, Kalmbach M, Lee JH, Ordog T, Hampel PJ, Call TG, Witzig TE, Kay NE, Klee EW, Slager SL, Yan H, Ding W. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Sci Rep. 2021 Apr 15; 11 (1):8318
    View PubMed
22. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
23. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
24. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020 Oct; 61 (10):2383-2388 Epub 2020 May 25
    View PubMed
25. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020 Sep 22; 4 (18):4508-4511
    View PubMed
26. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
27. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019 Nov; 60 (11):2712-2719 Epub 2019 Apr 24
    View PubMed
28. Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018 Nov; 183 (3):421-427 Epub 2018 Aug 16
    View PubMed
29. Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Coelho-Prabhu N, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018 Jul; 88 (1):55-61 Epub 2018 Feb 02
    View PubMed
30. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 2018 Jun; 103 (6):e237-e240 Epub 2018 Feb 01
    View PubMed
31. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017 Dec; 92 (12):1362-1369 Epub 2017 Oct 19
    View PubMed
32. Hampel PJ, Chela H, Irish J, Parker R. Isolated Intestinal Angioedema Induced by an ACE-inhibitor Journal of Academic Hospital Medicine. 2015; 7(3).
    
33. Hong Z, Ersoy I, Sun M, Bunyak F, Hampel P, Hong Z, Sun Z, Li Z, Levitan I, Meininger GA, Palaniappan K. Influence of membrane cholesterol and substrate elasticity on endothelial cell spreading behavior. J Biomed Mater Res A. 2013 Jul; 101 (7):1994-2004 Epub 2012 Dec 13
    View PubMed
34. Hong Z, Staiculescu MC, Hampel P, Levitan I, Forgacs G. How cholesterol regulates endothelial biomechanics. Front Physiol. 2012; 3:426 Epub 2012 Nov 15
    View PubMed
35. Hong Z, Luz GM, Hampel PJ, Jin M, Liu A, Chen X, Mano JF. Mono-dispersed bioactive glass nanospheres: preparation and effects on biomechanics of mammalian cells. J Biomed Mater Res A. 2010 Dec 1; 95 (3):747-54
    View PubMed